Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC.CNCE · Entity 115906 | Director | June 14, 2018 | June 18, 2018 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | Director | September 16, 2026 | September 18, 2026 |
| TENET HEALTHCARE CORPTHC · Entity 2563 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONCERT PHARMACEUTICALS, INC.
Report date June 14, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.59 · Expires 2028-06-13 | Direct | 10,000 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. |
| Nonstatutory Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.59 · Expires 2028-06-13 | Direct | 13,453 |
Reported balance
After 2018-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-14 · Grant · Acquired 3,453 · Balance 13,453 F1: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. F2: These options were awarded to the director per such director's election to receive annual cash compensation in the form of stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019.
F2: These options were awarded to the director per such director's election to receive annual cash compensation in the form of stock options.
Roivant Sciences Ltd.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 41,162 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 5,054 · Balance 41,162 F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.57 · Expires 2036-09-15 | Direct | 10,531 |
Reported balance
After 2026-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-16 · Grant · Acquired 10,531 · Balance 10,531 F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
TENET HEALTHCARE CORP
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2026 May Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-05-27 | Direct | 1,188 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 1,188 · Balance 1,188 F1: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pear Therapeutics, Inc.
Report date December 03, 2021 · Filed December 07, 2021
Section 16 reporting ended · disclosed 2021-12-07. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 22:57 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 10,531 | $0.00 Strike: $39.57 | $0.00 |
DisclosureSEC source: 0001349297-26-000010 · wk-form4_1789772242.xml · derivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,531 Underlying: Common Shares · 10,531 shares Expires 2036-09-15 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:57 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 5,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001349297-26-000010 · wk-form4_1789772242.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,162 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 22:42 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 400 | $40.45 | $16,180.00 |
DisclosureSEC source: 0001349297-26-000008 · wk-form4_1789684933.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,108 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.28 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 22:42 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 4,712 | $39.68 | $186,972.16 |
DisclosureSEC source: 0001349297-26-000008 · wk-form4_1789684933.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,508 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:29 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 1,743 | $40.94 | $71,358.42 |
DisclosureSEC source: 0001349297-26-000006 · wk-form4_1789424944.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,220 F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001140361-26-036246 · form4.xml · derivative · entry 3 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,578 Underlying: Common Stock · 20,000 shares Expires 2033-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 20,000 | $39.90 | $798,000.00 |
DisclosureSEC source: 0001140361-26-036246 · form4.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,963 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 20,000 | $8.80 | $176,000.00 |
DisclosureSEC source: 0001140361-26-036246 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:03 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001349297-26-000004 · wk-form4_1783033435.xml · derivative · entry 3 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,578 Underlying: Common Stock · 10,000 shares Expires 2033-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:03 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 10,000 | $34.90 | $349,000.00 |
DisclosureSEC source: 0001349297-26-000004 · wk-form4_1783033435.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,963 Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:03 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 10,000 | $8.80 | $88,000.00 |
DisclosureSEC source: 0001349297-26-000004 · wk-form4_1783033435.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2026 Filed May 29, 2026 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Grant2026 May Restricted Stock Units · Derivative | 1,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-245804 · ownership.xml · derivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,188 Underlying: Common Stock · 1,188 shares Expires 2027-05-27 F1 · derivative.exercise_price: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. Read SEC document |
| May 22, 2026 Filed May 27, 2026 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Exercise / conversion2025 May Restricted Stock Units · Derivative | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-239938 · ownership.xml · derivative · entry 3 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,333 shares Expires 2026-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. The reporting person settled 37% of his restricted stock units for cash and 63% for shares of THC common stock. F1 · price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. The reporting person settled 37% of his restricted stock units for cash and 63% for shares of THC common stock. Read SEC document |
| May 22, 2026 Filed May 27, 2026 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Disposition to issuerCommon Stock | 493 | $173.78 | $85,673.54 |
DisclosureSEC source: 0001193125-26-239938 · ownership.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,087 Read SEC document |
| May 22, 2026 Filed May 27, 2026 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Exercise / conversionCommon Stock | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-239938 · ownership.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. The reporting person settled 37% of his restricted stock units for cash and 63% for shares of THC common stock. Read SEC document |
| March 26, 2026 Filed Mar 31, 2026 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001140361-26-012063 · form4.xml · derivative · entry 3 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,578 Underlying: Common Stock · 70,000 shares Expires 2033-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| March 26, 2026 Filed Mar 31, 2026 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 70,000 | $27.45 | $1,921,500.00 |
DisclosureSEC source: 0001140361-26-012063 · form4.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,963 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.32 to $27.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| March 26, 2026 Filed Mar 31, 2026 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 70,000 | $8.80 | $616,000.00 |
DisclosureSEC source: 0001140361-26-012063 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 33,726 | $0.00 Strike: $13.77 | $0.00 |
DisclosureSEC source: 0001140361-25-034932 · form4.xml · derivative · entry 3 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,726 Underlying: Common Shares · 33,726 shares Expires 2035-09-09 F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 937 | $13.77 | $12,902.49 |
DisclosureSEC source: 0001140361-25-034932 · form4.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,963 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 14,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-034932 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,900 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| May 23, 2025 Filed May 28, 2025 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Exercise / conversionRestricted Stock Units · Derivative | 1,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-078016 · ownership.xml · derivative · entry 4 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,551 shares Expires 2025-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. The reporting person settled 37% of her restricted stock units for cash and 63% for shares of THC common stock. F1 · price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. The reporting person settled 37% of her restricted stock units for cash and 63% for shares of THC common stock. Read SEC document |
| May 23, 2025 Filed May 28, 2025 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Disposition to issuerCommon Stock | 573 | $161.33 | $92,442.09 |
DisclosureSEC source: 0000950170-25-078016 · ownership.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,247 Read SEC document |
| May 23, 2025 Filed May 28, 2025 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Exercise / conversionCommon Stock | 1,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-078016 · ownership.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. The reporting person settled 37% of her restricted stock units for cash and 63% for shares of THC common stock. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-078016 · ownership.xml · derivative · entry 3 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2026-05-22 F2 · derivative.exercise_price: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 894 | $12.12 | $10,835.28 |
DisclosureSEC source: 0001140361-24-041230 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,376 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 27,894 | $0.00 Strike: $12.19 | $0.00 |
DisclosureSEC source: 0001140361-24-040986 · form4.xml · derivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,894 Underlying: Common Shares · 27,894 shares Expires 2034-09-09 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 16,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-040986 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,270 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| August 06, 2024 Filed Aug 9, 2024 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | SaleCommon Stock | 20,000 | $146.34 | $2,926,800.00 |
DisclosureSEC source: 0000950170-24-094286 · ownership.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,269 F1 · price: The price is the weighted average sales price of the aggregate number of shares that were sold by the reporting person. These shares were sold in multiple transactions at prices ranging from $146.16 to $146.68. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantRestricted Stock Units · Derivative | 1,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-065554 · ownership.xml · derivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,551 Underlying: Common Stock · 1,551 shares Expires 2025-05-23 F1 · derivative.exercise_price: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. Read SEC document |
| April 24, 2024 Filed Apr 27, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 83 | $10.90 | $904.70 |
DisclosureSEC source: 0001140361-24-022618 · form4.xml · nonDerivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,864 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| April 24, 2024 Filed Apr 27, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-022618 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,947 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| January 19, 2024 Filed Jan 24, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-003553 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,686 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-048774 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,358 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 13,334 | $0.00 Strike: $11.22 | $0.00 |
DisclosureSEC source: 0001140361-23-044044 · form4.xml · derivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Shares · 13,334 shares Expires 2033-09-11 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 8,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-044044 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,089 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
| July 03, 2023 Filed Jul 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-033546 · form4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| May 26, 2023 Filed May 30, 2023 21:14 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 2,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032941 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,433 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). Read SEC document |
| May 26, 2023 Filed Jun 23, 2023 23:08 UTC Amendment | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 3,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039535 · doc4a.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,269 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F2 · shares: This amendment is being filed to correct the amount of restricted stock units granted on May 26, 2023. Read SEC document |
| April 20, 2023 Filed Apr 25, 2023 01:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 118,578 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001140361-23-019995 · form4.xml · derivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,578 Underlying: Common Shares · 118,578 shares Expires 2033-04-19 F1 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of March 13, 2023. These options vest and become exercisable (i) 1/3 on the first anniversary of the vesting commencement date and (ii) in twenty-four (24) successive equal monthly installments measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:45 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 3,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028333 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,587 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:36 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | SaleCommon Stock | 6,077 | $72.70 | $441,797.90 |
DisclosureSEC source: 0001209191-21-056915 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,751 F1 · kind: These shares were sold in an open market broker transaction. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:44 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | SaleCommon Stock | 6,153 | $63.57 | $391,146.21 |
DisclosureSEC source: 0001209191-21-035948 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,828 F1 · kind: These shares were sold in open market broker transactions. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:47 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-031803 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,981 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 23:12 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 11,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-033748 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,021 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 22:15 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | PurchaseCommon Stock | 6,153 | $13.02 | $80,112.06 |
DisclosureSEC source: 0001209191-20-020079 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,882 F1 · shares: The shares were purchased in open market broker transactions. F2 · price: The price is the weighted average purchase price of the aggregate number of shares that were purchased by the reporting person. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.04. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 03, 2019 Filed May 7, 2019 21:56 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 10,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028054 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,729 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 22:58 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 3,453 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0000899243-18-017077 · doc4.xml · derivative · entry 2 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,453 Underlying: Common Stock · 3,453 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. F2 · derivative.exercise_date: These options were awarded to the director per such director's election to receive annual cash compensation in the form of stock options. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 22:58 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0000899243-18-017077 · doc4.xml · derivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:46 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 7,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035345 · doc4.xml · nonDerivative · entry 1 Fitzgerald Meghan · CIK 0001349297 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,912 F1 · security: Represents restricted stock units granted to new non-employee director upon appointment to Board of Directors pursuant to the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date. 1,835 restricted stock units will be settled in shares of common stock upon termination of service from the Board and 6,077 will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted to new non-employee director upon appointment to Board of Directors pursuant to the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date. 1,835 restricted stock units will be settled in shares of common stock upon termination of service from the Board and 6,077 will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.